166 related articles for article (PubMed ID: 7894538)
1. Tolerance to a new class of non-benzodiazepine anxiolytics.
Chodera A; Nowakowska E; Bartczak G
Pol J Pharmacol; 1994; 46(5):479-81. PubMed ID: 7894538
[TBL] [Abstract][Full Text] [Related]
2. Anticonvulsant, anxiolytic, and non-sedating actions of imidazenil and other imidazo-benzodiazepine carboxamide derivatives.
Auta J; Kadriu B; Giusti P; Costa E; Guidotti A
Pharmacol Biochem Behav; 2010 Jun; 95(4):383-9. PubMed ID: 20227434
[TBL] [Abstract][Full Text] [Related]
3. Zolpidem and alpidem: two imidazopyridines with selectivity for omega 1- and omega 3-receptor subtypes.
Langer SZ; Arbilla S; Benavides J; Scatton B
Adv Biochem Psychopharmacol; 1990; 46():61-72. PubMed ID: 1981304
[No Abstract] [Full Text] [Related]
4. Reduction of reticulata neuronal activity by zolpidem and alpidem, two imidazopyridines with high affinity for type I benzodiazepine receptors.
Mereu G; Carcangiu G; Concas A; Passino N; Biggio G
Eur J Pharmacol; 1990 Apr; 179(3):339-45. PubMed ID: 1973107
[TBL] [Abstract][Full Text] [Related]
5. Oral buspirone causes a shift in the dose-response curve between the elevated-plus maze and Vogel conflict tests in Long-Evans rats: relation of brain levels of buspirone and 1-PP to anxiolytic action.
Vaidya AH; Rosenthal DI; Lang W; Crooke JJ; Benjamin D; Ilyin SE; Reitz AB
Methods Find Exp Clin Pharmacol; 2005 May; 27(4):245-55. PubMed ID: 16082425
[TBL] [Abstract][Full Text] [Related]
6. Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents.
Griebel G; Perrault G; Sanger DJ
J Psychopharmacol; 1998; 12(4):356-65. PubMed ID: 10065909
[TBL] [Abstract][Full Text] [Related]
7. Comparative autoradiographic distribution of central omega (benzodiazepine) modulatory site subtypes with high, intermediate and low affinity for zolpidem and alpidem.
Benavides J; Peny B; Ruano D; Vitorica J; Scatton B
Brain Res; 1993 Feb; 604(1-2):240-50. PubMed ID: 8096157
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological and behavioral profile of alpidem as an anxiolytic.
Zivkovic B; Morel E; Joly D; Perrault G; Sanger DJ; Lloyd KG
Pharmacopsychiatry; 1990 May; 23 Suppl 3():108-13. PubMed ID: 1974069
[TBL] [Abstract][Full Text] [Related]
9. Buspirone attenuates conditioned fear-induced c-Fos expression in the rat hippocampus.
Wisłowska-Stanek A; Zienowicz M; Lehner M; Taracha E; Bidziński A; Maciejak P; Skórzewska A; Szyndler J; Płaźnik A
Neurosci Lett; 2005 Dec; 389(2):115-20. PubMed ID: 16095819
[TBL] [Abstract][Full Text] [Related]
10. Benzodiazepine receptor binding of nonbenzodiazepines in vivo: alpidem, zolpidem and zopiclone.
Byrnes JJ; Greenblatt DJ; Miller LG
Brain Res Bull; 1992 Dec; 29(6):905-8. PubMed ID: 1361878
[TBL] [Abstract][Full Text] [Related]
11. The effect of glucocorticoids on the anxiolytic efficacy of buspirone.
Haller J; Leveleki C; Halász J; Baranyi J; Makara GB
Psychopharmacology (Berl); 2001 Oct; 157(4):388-94. PubMed ID: 11605098
[TBL] [Abstract][Full Text] [Related]
12. Antagonist-induced reversal of functional and structural measures of hippocampal benzodiazepine tolerance.
Tietz EI; Zeng XJ; Chen S; Lilly SM; Rosenberg HC; Kometiani P
J Pharmacol Exp Ther; 1999 Dec; 291(3):932-42. PubMed ID: 10565808
[TBL] [Abstract][Full Text] [Related]
13. Oxidative metabolism of limbic structures after acute administration of diazepam, alprazolam and zolpidem.
González-Pardo H; Conejo NM; Arias JL
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1020-6. PubMed ID: 16647177
[TBL] [Abstract][Full Text] [Related]
14. Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone.
Harada K; Aota M; Inoue T; Matsuda R; Mihara T; Yamaji T; Ishibashi K; Matsuoka N
Eur J Pharmacol; 2006 Dec; 553(1-3):171-84. PubMed ID: 17074317
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological evaluation of the stress-induced social avoidance model of anxiety.
Leveleki C; Sziray N; Levay G; Barsvári B; Soproni K; Mikics E; Haller J
Brain Res Bull; 2006 Mar; 69(2):153-60. PubMed ID: 16533664
[TBL] [Abstract][Full Text] [Related]
16. Anxiolytic and memory improving activity of fluoxetine.
Nowakowska E; Chodera A; Kus K
Pol J Pharmacol; 1996; 48(3):255-60. PubMed ID: 9112660
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of non-benzodiazepine anxiolytics.
Lader M
Pharmacol Biochem Behav; 1988 Apr; 29(4):797-8. PubMed ID: 2901119
[TBL] [Abstract][Full Text] [Related]
18. The effect of social factors on the anxiolytic efficacy of buspirone in male rats, male mice, and men.
Majercsik E; Haller J; Leveleki C; Baranyi J; Halász J; Rodgers RJ
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Dec; 27(8):1187-99. PubMed ID: 14659474
[TBL] [Abstract][Full Text] [Related]
19. Development of differential tolerance to the sedative and anti-stress effects of benzodiazepines.
Mediratta PK; Sharma KK; Rana J
Indian J Physiol Pharmacol; 2001 Jan; 45(1):111-5. PubMed ID: 11211563
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem.
Chouinard G; Lefko-Singh K; Teboul E
Cell Mol Neurobiol; 1999 Aug; 19(4):533-52. PubMed ID: 10379424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
